Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout
Authors' conclusion
Gout flare rates were persistently higher when SU ≥6 mg/dL after the first year of ULT after accounting for censoring.
Study context
- Population
- Participants with gout randomised to febuxostat or allopurinol, titrated to target serum urate (SU) <6 mg/dL with flare prophylaxis for 6 months (CARES trial)median age 65 years
- Participants
- 6,183 participants
- Comparison
- Time-varying SU categories vs SU 4.0-5.9 mg/dL
- Primary endpoint
- Gout flare (incidence rate ratios by time-varying SU category)
Methodological detailspost hoc cohort analysis, Poisson regression adjusted for covariates and factors related to retention vs dropout, time-varying SU category
- Post hoc cohort analysis
- Poisson regression adjusted for covariates and factors related to retention vs dropout
- Time-varying SU category
Primary result
As reported in the abstract
Gout flare rate by SU category · months 36-72
- Dose-response relationship between SU category and flare rate; lower flare rates with SU ≤3.9 mg/dL and greater rates with SU ≥10 mg/dL vs SU 4.0-5.9 mg/dL
- p for trend <0.01
Further findings
Gout flare rates in the initial year of urate-lowering therapy (ULT) · months 0-12
- Flare rates similar across SU groups in the initial year of ULT
- Peak flare rates for all SU categories in months 0-6 (ULT initiation) and months 6-12 (after stopping prophylaxis)
Original publication
Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →